|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumours showed strong nuclear immunoreactivity for TFE3.
|
30908700 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Malignant TFE3-rearranged perivascular epithelioid cell neoplasm (PEComa) presenting as a subcutaneous mass.
|
26385848 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, 5 tumors showed a positive reaction for TFE3 with a range from 1+ to 2+ in intensity.No tumors were positive for TFEB.
|
21424937 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor cells were positive for TFE3 and CK.
|
28478739 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PEComas constitute a genetically diverse group that includes neoplasms harboring TFE3 gene rearrangements and those with TSC2 mutations, indicating alternative tumorigenic pathways.
|
26144278 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the tumor demonstrated moderately (2+) or strongly (3+) positive staining for TFEB, Cathepsin K, Ksp-cadherin, and vimentin but negative for TFE3, CD10, HMB45, melan A, CKpan, and CK7.
|
23826432 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The PEComa-like tumor showed strong Melan-A and weak transcription factor E3 (TFE3) protein expression but no TFE3 gene rearrangement.
|
30876389 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The most distinctive immunohistochemical feature of these neoplasms was moderate to intense nuclear labeling for TFE3 protein.
|
12459622 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results also suggest that adult RCC with TFE3 rearrangement may be a clinically aggressive tumor.
|
22498819 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One tumor, currently at passage 6, has been maintained in vivo for 32 months and has maintained characteristics consistent with those of the original ASPS tumor including (1) tumor histology and staining with periodic acid Schiff/diastase, (2) the presence of the ASPL-TFE3 type 1 fusion transcript, (3) nuclear staining with antibodies to the ASPL-TFE3 type 1 fusion protein, (4) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS, (5) stable expression of signature ASPS gene transcripts and finally, the development and maintenance of a functional vascular network, a hallmark of ASPS.
|
19636271 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our TFE3 FISH assay is a useful adjunct to morphologic analysis of such challenging cases and will be applicable to assess the growing spectrum of TFE3-rearranged tumors.
|
23828314 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica.
|
27189222 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As the true frequency of these neoplasms as well as the biological properties of TFE3 activation in renal cell carcinomas are largely unknown, we have examined TFE3 expression as well as the underlying genetic alterations in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.
|
22037260 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3 regulates both Golgi and lysosomal homeostasis and is rearranged in renal cell carcinoma (RCC), alveolar soft part sarcoma, epithelioid hemangioendothelioma, and perivascular epitheloid cell tumors (PEComas).
|
31774608 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequence analysis demonstrated reciprocal ASPL-TFE3 and TFE3-ASPL fusion transcripts in the retroperitoneal tumor, cultured FU-UR-1 cells and xenografted tumors.
|
15138551 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms.
|
29212159 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor showed nuclear labeling for TFE3 protein by immunohistochemistry, supporting the above diagnosis.
|
16807766 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, an increasing number of TFE3 rearrangement-associated tumours have been reported, such as TFE3 rearrangement-associated perivascular epithelioid cell tumours (PEComas), melanotic Xp11 translocation renal cancers and melanotic Xp11 neoplasms.
|
26844676 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Kidney-specific cadherin, cytokeratin 34betaE12 and TFE3 stains were negative in the tumor.
|
24702883 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation revealed that the tumor cells showed nuclear labeling for TFE3 protein.
|
19298350 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The morphologic and immunohistochemical discrepancies between this intriguing melanotic tumor and other documented renal cell carcinomas bearing identical PSF-TFE3 gene fusion may suggest melanotic Xp11 translocation renal cancer is a distinct entity among the MiT/TFE family neoplasms.
|
19809274 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3.
|
21552147 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation on the biopsy reveals that the tumor is positive for PAX-8, CD10, and TFE3.
|
28877071 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retaining the TFE3 DNA-binding domain, implicating transcriptional deregulation in the pathogenesis of this tumor, consistent with the biology of several other translocation-associated sarcomas.Oncogene (2001) 20, 48 - 57.
|
11244503 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the present study was to figure out in two pediatric RCC recently diagnosed in our department (one clear cell-type RCC and one TFE3-positive RCC) whether those features are indeed specific of the latter tumor or occur in pediatric RCC irrespective of the tumor type.
|
19246164 |
2009 |